Neuphoria Therapeutics Inc
NEUP3.890USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
9.17MMarket Cap
LossP/E TTM
More Details of Neuphoria Therapeutics Inc Company
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Neuphoria Therapeutics Inc Info
Ticker SymbolNEUP
Company nameNeuphoria Therapeutics Inc
IPO dateDec 21, 1999
CEOPapapetropoulos (Spyridon)
Number of employees7
Security typeOrdinary Share
Fiscal year-endDec 21
Address100 Summit Dr
CityBURLINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01803
Phone
Websitehttps://www.neuphoriatx.com/
Ticker SymbolNEUP
IPO dateDec 21, 1999
CEOPapapetropoulos (Spyridon)
Company Executives of Neuphoria Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jane Ryan, Ph.D.
Dr. Jane Ryan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
230.00
--
Mr. Peter Miles Winston (Miles Davies) Davies
Mr. Peter Miles Winston (Miles Davies) Davies
Non-Executive Independent Director
Non-Executive Independent Director
126.00
--
Mr. David Ian Wilson
Mr. David Ian Wilson
Non-Executive Director
Non-Executive Director
117.00
--
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Timothy M. (Tim) Cunningham, CPA
Mr. Timothy M. (Tim) Cunningham, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Liz Doolin
Ms. Liz Doolin
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Mr. Alan Fisher
Mr. Alan Fisher
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jane Ryan, Ph.D.
Dr. Jane Ryan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
230.00
--
Mr. Peter Miles Winston (Miles Davies) Davies
Mr. Peter Miles Winston (Miles Davies) Davies
Non-Executive Independent Director
Non-Executive Independent Director
126.00
--
Mr. David Ian Wilson
Mr. David Ian Wilson
Non-Executive Director
Non-Executive Director
117.00
--
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Timothy M. (Tim) Cunningham, CPA
Mr. Timothy M. (Tim) Cunningham, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Liz Doolin
Ms. Liz Doolin
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Australia
165.49K
0.00%
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 15
Updated: Mon, Dec 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
16.28%
Baselake Management, LLC
4.13%
Robert (Eleanor Lipyanek)
3.23%
Shay Capital LLC
3.19%
Coastlands Capital LP
2.23%
Other
70.94%
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
16.28%
Baselake Management, LLC
4.13%
Robert (Eleanor Lipyanek)
3.23%
Shay Capital LLC
3.19%
Coastlands Capital LP
2.23%
Other
70.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.48%
Hedge Fund
6.26%
Corporation
4.32%
Individual Investor
3.42%
Family Office
1.35%
Research Firm
0.29%
Investment Advisor/Hedge Fund
0.24%
Bank and Trust
0.02%
Other
65.61%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
29
179.66K
8.11%
-2.95M
2025Q2
33
6.79M
41.79%
+3.53M
2025Q1
33
6.78M
41.76%
+3.58M
2024Q4
32
7.37M
43.34%
+1.92M
2024Q3
28
10.93M
60.28%
+6.68M
2024Q2
22
3.20M
28.02%
+971.25K
2024Q1
21
2.12M
20.11%
-221.89K
2023Q4
19
2.39M
22.66%
-332.20K
2023Q3
16
3.51M
33.26%
+2.99M
2023Q2
8
471.38K
5.30%
-62.88K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lynx1 Capital Advisors LLC
45.81K
1.94%
--
--
Jun 30, 2025
Robert (Eleanor Lipyanek)
173.72K
7.37%
+173.72K
--
Sep 25, 2025
Apeiron Investment Group Ltd
72.62K
3.08%
-592.38K
-89.08%
Jan 24, 2025
AdvisorShares Investments, LLC
67.73K
2.87%
-1.93K
-2.76%
Jun 30, 2025
Prosperity Wealth Management, Inc.
29.75K
1.26%
+2.55K
+9.38%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
2.81%
AdvisorShares Psychedelics ETF
Proportion2.81%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Neuphoria Therapeutics Inc?
The top five shareholders of Neuphoria Therapeutics Inc are:
Lynx1 Capital Advisors LLC holds 45.81K shares, accounting for 1.94% of the total shares.
Robert (Eleanor Lipyanek) holds 173.72K shares, accounting for 7.37% of the total shares.
Apeiron Investment Group Ltd holds 72.62K shares, accounting for 3.08% of the total shares.
AdvisorShares Investments, LLC holds 67.73K shares, accounting for 2.87% of the total shares.
Prosperity Wealth Management, Inc. holds 29.75K shares, accounting for 1.26% of the total shares.
Lynx1 Capital Advisors LLC holds 45.81K shares, accounting for 1.94% of the total shares.
Robert (Eleanor Lipyanek) holds 173.72K shares, accounting for 7.37% of the total shares.
Apeiron Investment Group Ltd holds 72.62K shares, accounting for 3.08% of the total shares.
AdvisorShares Investments, LLC holds 67.73K shares, accounting for 2.87% of the total shares.
Prosperity Wealth Management, Inc. holds 29.75K shares, accounting for 1.26% of the total shares.
What are the top three shareholder types of Neuphoria Therapeutics Inc?
The top three shareholder types of Neuphoria Therapeutics Inc are:
Lynx1 Capital Advisors LLC
Baselake Management, LLC
Robert (Eleanor Lipyanek)
Lynx1 Capital Advisors LLC
Baselake Management, LLC
Robert (Eleanor Lipyanek)
How many institutions hold shares of Neuphoria Therapeutics Inc (NEUP)?
As of 2025Q3, 29 institutions hold shares of Neuphoria Therapeutics Inc, with a combined market value of approximately 179.66K, accounting for 8.11% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -33.68%.
What is the biggest source of revenue for Neuphoria Therapeutics Inc?
In FY2020, the -- business generated the highest revenue for Neuphoria Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
